Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.

Authors
Publication date
25 December 2023
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Ezid

    redirect
    oaiark:/13030/qt0hn9g90m
    Last time updated on 24/06/2024